EXPANSION ADDS STATE-OF-THE-ART UPSTREAM AND DOWNSTREAM GMP PROCESSING CAPABILITIES TO MEET THE GROWING DEMAND FOR 2,000 ...

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and ...

Creative Diagnostics announces the release of a specialized portfolio of Antibiotic Residue Detection ELISA Kits. NEW ...

Agenus (NASDAQ:AGEN) used its first 2026 stakeholder webcast to outline operational and clinical priorities tied to its ...

WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development and manufacturing of innovative bispecific antibody: Shanghai Friday, January 30, 2026, 10:00 Hrs [IST ...

WuXi Biologics and Sinorda Biomedicine have jointly announced a strategic collaboration for the development and manufacturing of SND006.

HanchorBio and WuXi Biologics collaborate to develop fusion proteins using the Fc-Based Designer Biologics platform, ...

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein ...

On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, ...

INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has received the ...

BioDlink, a leading global contract development and manufacturing organization (CDMO), has released a white paper titled ...

WuXi Biologics says the company will provide the partnership with integrated, end-to-end biologics development and manufacturing services.